Simcere gets plants approved by China, Recipharm by Japan; GSK checks tech for cheaper vaccine making;

> China's Simcere Pharmaceutical Group said the State Food and Drug Administration (SFDA) in China has approved its production facility in Jiangsu to manufacture influenza vaccine. Release

> Keystone Laboratories, an OTC product manufacturer based in Bozeman, MT, has been warned by the FDA to improve its dirty manufacturing facility in Memphis or face the possibility of having products seized. Warning letter

> GlaxoSmithKline ($GSK) has licensed technology from a U.K. institute for more cheaply manufacturing polio vaccine which could be utilized in developing countries. Story

> U.S. private equity firm Arlington Capital Partners has provided backing for the management buyout of Micron Technologies, betting on growth in API particle engineering. Report

> The solid-dose facility of Recipharm in Fontaine, France, has been approved by Japan's PMDA to manufacture drugs for the Japanese market. Release

> DHL Global Forwarding has opened a temperature-controlled pharmaceutical distribution facility in Barcelona that includes four loading bays, a security area for psychotropic substances, a loading area for envirotainers and an area for refuse in safety cages. Item 

And Finally... Australia and New Zealand have taken a step toward combined oversight for drugmakers in the two countries with a new process for reviewing new and changed over-the-counter products. Item